Research Paper Volume 14, Issue 16 pp 6467—6480
Effect of BBT-877, a novel inhibitor of ATX, on a mouse model of type 1 diabetic nephropathy
Figure 1. BBT-877 attenuates hyperglycemia and dyslipidemia in STZ-induced diabetic mice. After mice were administered BBT-877 for 8 weeks, measurements were taken for (A) blood glucose, (B) HbA1c, (C) Triglyceride, and (D) LDL-cholesterol. Abbreviations: STZ: streptozotocin; HbA1c: glycosylated hemoglobin. STZ-10BBT: BBT-877 10 mg/kg, STZ-30BBT: BBT-877 30 mg/kg, STZ-90BBT: BBT-877 90 mg/kg, STZ-10L: losartan 10 mg/kg. *p < 0.05, control-vehicle vs. STZ-vehicle, #p < 0.05, STZ-vehicle vs. STZ-10, 30, 90BBT or STZ-10L, n = 8−10.